Back to Market返回行情

RCEL AVITA Medical, Inc.

USHealthcare
$4.06-7.94%ClosedMarket Cap: $100.9M

As of 2026-07-10 16:00

Why RCEL matters now

AVITA Medical, Inc. (RCEL) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.06 with -7.94% on the session and $100.9M in market capitalization; recent performance reads 1-month -4.52% and YTD +16.23%.

The latest financial table shown here is Q1 2026, with revenue of $19.3M, net income of $-10.6M, and EPS of $-34.74. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -30.9%.

The latest indexable market news headline is "Avita Medical (RCEL) Upgraded to Buy: Here's Why" from Zacks Investment Research.

Additional event context on this page matters because analyst consensus is Buy with a median target of $8.00; recent insider activity includes O'Toole David D filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

-0.05

P/S

1.38

EV/EBITDA

-2.47

DCF Value

$-31.16

FCF Yield

-30.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

81.4%

Operating Margin

-54.6%

Net Margin

-62.7%

ROE

305.4%

ROA

-88.0%

ROIC

-127.4%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$19.3M$-10.6M$-34.74
Q4 2025$17.6M$-11.6M$-0.38
FY 2025$71.6M$-48.6M$-1.74
Q3 2025$17.1M$-13.2M$-0.46

Analyst Ratings

Consensus

Buy

Target (Consensus)

$8.00

Target (Median)

$8.00

Target Range

$6.00 - $10.00

Strong Buy: 0Buy: 3Hold: 1Sell: 0Strong Sell: 0
Lake StreetBuy
2026-05-15
D. Boral CapitalBuy
2026-04-09
D. Boral CapitalBuy
2026-02-17
Lake StreetHold
2026-01-16
D. Boral CapitalBuy
2026-01-15

Trading Activity

Insider Trades

O'Toole David Dofficer: CFO
Sell2026-06-12
Woody Joseph Fralindirector
Buy2026-06-10
Woody Joseph Fralindirector
Buy2026-06-09
Woody Joseph Fralindirector
Buy2026-06-09
Woody Joseph Fralindirector
Buy2026-06-05

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

1.86

AVITA Medical, Inc. is a leading company focused on regenerative tissue, actively commercializing its innovative products across the United States, Australia, and the United Kingdom. The company's mission is to fulfill critical medical needs in areas such as severe burn and trauma injuries, chronic wounds, and various dermatological and aesthetic concerns, including vitiligo. At the core of its operations is a patented and proprietary technology platform that harnesses the natural regenerative properties found within a patient's own skin to develop therapeutic solutions. Their flagship product, the RECELL System, is a sophisticated medical device. It allows healthcare providers to prepare a suspension of "Spray-On Skin" cells directly from a small sample of the patient's healthy skin. This pioneering treatment is primarily approved for use in adults aged eighteen and older who have sustained acute thermal burns. Beyond its commercial activities, AVITA Medical is deeply invested in forward-thinking research. The company has a partnership with the University of Colorado School of Medicine, dedicated to exploring the preclinical viability of a spray-on application for genetically corrected cells. Furthermore, a collaboration with the Houston Methodist Research Institute aims to investigate the molecular processes involved in reversing cellular aging through an advanced cell suspension delivery system. Founded in 2000 and headquartered in Valencia, California, the company previously operated as AVITA Therapeutics, Inc. before officially changing its name to AVITA Medical Inc. in December 2020.